Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models

Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models

Immune checkpoint blockade (ICB) is currently evaluated in patients with glioblastoma (GBM), based on encouraging clinical data in other cancers, and results from studies with the methylcholanthrene-induced GL261 mouse glioma. In this paper, we describe a novel model faithfully recapitulating some k...

Full description

Bibliographic Details
Main Authors: Vassilis Genoud, Eliana Marinari, Sergey I Nikolaev, John C. Castle, Valesca Bukur, Pierre-Yves Dietrich, Hideho Okada, Paul R. Walker
Format: Article
Language:English
Published: Taylor & Francis Group 2018-12-01
Series:OncoImmunology
Subjects:
immune checkpoint blockade
glioblastoma
gl261
sb28
mutational load
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1501137

Internet

http://dx.doi.org/10.1080/2162402X.2018.1501137

Similar Items